What category does this event fall under?

Business — classified as securities lawsuit.

What is the sentiment of coverage?

Aggregate sentiment score: -70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Business securities lawsuit

Medpace Securities Fraud Lawsuits

Q: When did this event occur?

First reported Apr 07, 2026; last updated May 20, 2026.

Q: Who was involved?

Top entities: Jesse Geiger, United States — United States District Court for the Southern District of Ohio, Tesla, Inc., Rosen Law Firm, Philip Kim.

Q: What is the market impact?

General. The class action lawsuits against Medpace for securities fraud, coupled with the company's reported elevated cancellation rates and declining book-to-bill ratio, have led to significant drops in Medpace's stock price.

Analysis based on 100 articles · First reported Apr 07, 2026 · Last updated May 20, 2026

Sentiment

-70

Attention

Articles

100

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The class action lawsuits against Medpace for securities fraud, coupled with the company's reported elevated cancellation rates and declining book-to-bill ratio, have led to significant drops in Medpace's stock price. This event creates uncertainty for investors in Medpace and highlights the risks associated with alleged corporate misrepresentations in the biotechnology, pharmaceutical, and medical device industries.

biotechnology pharmaceutical medical device

Event Summary

Medpace Holdings Inc. is facing multiple class action lawsuits for securities fraud. Law firms including Rosen Law Firm, The Schall Law Firm, and Bleichmar Fonti & Auld LLP have filed suits alleging that Medpace and its senior executives made false and misleading statements regarding the company's backlog cancellation rates and book-to-bill ratio. These alleged misrepresentations led to a nearly 16% stock drop on February 9, 2026, after Medpace reported a decline in its 4Q 2025 book-to-bill ratio due to elevated cancellations. Further reports of increasing cancellations and a declining book-to-bill ratio to 0.88 for 1Q 2026, along with the resignation of President Jesse Geiger, caused another approximately 23% stock decline on April 23, 2026. Investors who purchased Medpace common stock during the Class Period (April 22, 2025, to February 9, 2026) are encouraged to join the lawsuits, with a lead plaintiff deadline of June 8, 2026.

Entities Involved

per

Jesse Geiger

Jesse Geiger, President of Medpace, announced his intention to resign, which contributed to a further decline in the company's stock price amidst the ongoing fraud allegations.

Importance 70.0 Sentiment -50.0

govactor

United States — United States District Court for the Southern District of Ohio

The United States — United States District Court for the Southern District of Ohio is the venue where the class action lawsuit Durbin v. Medpace Holdings Inc., et al., No. 1:26-cv-00346, is pending.

Importance 50.0 Sentiment 0.0

stock

Tesla, Inc.